The decision to steer its main antioxidant strategy away from a successful Phase I cancer program toward chronic kidney disease proved lucrative for Reata Pharmaceuticals Inc., which gained $35 million up front - and potentially much more as development moves ahead - through a deal centered on Nrf2-targeting bardoxolone with Kyowa Hakko Kirin Co. Ltd. (BioWorld Today) Read More
